Flat affect in Abilify - how severe and when it was recovered? (a real world drug study)

Summary:

We study how severe was Flat affect, when it was recovered, drug effectiveness, race, and more among people who take Abilify (aripiprazole). This phase IV clinical study is created by eHealthMe based on reports submitted to eHealthMe, and is updated regularly.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,451 Abilify users. Check the latest studies of Abilify.

What is Flat affect?

Flat affect (absence of emotional response to a situation) is found to be associated with 294 drugs and 458 conditions by eHealthMe. Check the latest studies of Flat affect.

On May, 21, 2026

9 people who have Flat affect while taking Abilify were studied.

Severity of Flat affect *:

least: 0.0 %
moderate: 33.33 %
severe: 66.67 %
most severe: 0.0 %

When people recovered from Flat affect *:

while on drug: 12.5 %
after off the drug: 0.0 %
not yet: 87.5 %

Effectiveness of Abilify *:

not at all: 11.11 %
somewhat: 0.0 %
moderate: 33.33 %
high: 44.44 %
very high: 11.11 %

Race of the people *:

African American, Non-Hispanic: 11.11 %
American Indian/Alaska Native: 11.11 %
Asian: 22.22 %
Hispanic: 0.0 %
Native Hawaiians/Pacific Islanders: 11.11 %
Two or more races: 0.0 %
White, Non-Hispanic: 44.44 %

Time on Abilify *:

Gender of people when taking Abilify *:

female: 33.33 %
male: 66.67 %

Age of people when taking Abilify *:

Conditions people have *:

Stress And Anxiety: 1 person, 11.11%
Schizophreniform Disorder (mental disorder is diagnosed when the symptom criteria for schizophrenia are met, but the duration is too short and social and occupational functioning): 1 person, 11.11%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 11.11%
Schizoaffective Disorder (a mental disorder characterized by disordered thought): 1 person, 11.11%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 11.11%
Psychotic Disorder: 1 person, 11.11%
Portal Hypertension (increase in the blood pressure within a system of veins called the portal venous system): 1 person, 11.11%
Panic Disorder: 1 person, 11.11%
Neuropathy Peripheral (surface nerve damage): 1 person, 11.11%
Nausea And Vomiting: 1 person, 11.11%

Other drugs people take besides Abilify *:

Lisinopril: 2 people, 22.22%
Lexapro: 2 people, 22.22%
Tysabri: 1 person, 11.11%
Topiramate: 1 person, 11.11%
Ritalin: 1 person, 11.11%
Risperdal: 1 person, 11.11%
Protonix: 1 person, 11.11%
Propranolol Hydrochloride: 1 person, 11.11%
Mirtazapine: 1 person, 11.11%
Lactulose: 1 person, 11.11%

Other side effects people have besides Flat affect *:

Anhedonia (inability to experience pleasure from activities usually found enjoyable): 3 people, 33.33%
Inappropriate Affect: 1 person, 11.11%
Anoxia (low oxygen): 1 person, 11.11%
Apathy: 1 person, 11.11%
Constricted Affect (limited affect): 1 person, 11.11%
Depression Suicidal (suicide depressive disorder): 1 person, 11.11%
Diabetes: 1 person, 11.11%
Disturbance In Attention: 1 person, 11.11%
Drooling (drop saliva uncontrollably from the mouth): 1 person, 11.11%
Feelings Of Worthlessness: 1 person, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and have Flat affect?

Check whether Flat affect is associated with a drug or a condition

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Flat affect in Abilify

How the study uses the data?

The study is based on aripiprazole (the active ingredients of Abilify). Other drugs that have the same active ingredients (e.g. generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.